Fig. 3.

Transferability and microtiter plate applicability of the new intramolecular receptor-biosensor design. BRET changes reported by β₂AR_Nluc/Halo618 expressing cells upon (a) saturating ligand stimulation (ICI 118.551: N = 6, Propranolol: N = 6, Metoprolol: N = 6, Carvedilol: N = 12, Labetalol: N = 16, Salbutamol: N = 8, Terbutaline: N = 8, Salmeterol: N = 11, Norepinephrine: N = 8, Formoterol: N = 11, Isoprenaline: N = 21, Epinephrine: N = 21) and b serial ligand dilutions to obtain concentration–response curves (Epnephrine: N = 4, Carvedilol: N = 4, ICI 118.551: N = 6). c Mean of the Z-factor of β₂AR_CFP/YFP and β₂AR_Nluc/Halo618 (each N = 4). BRET changes reported by PTHR1_Nluc/Halo618 expressing cells upon (d) saturating ligand stimulation (PTH(7-34): N = 12, (dW)-PTH(7-34): N = 12, PTH(3-34): N = 14, PTH(1-31): N = 6, PTHrP(1-34): N = 14,PTH(1-34): N = 22) and e serial ligand dilutions to obtain concentration–response curves (PTH(1-34): N = 3, PTHrP(1-34): N = 3, PTH(3-34): N = 6). f Mean of the Z-factor of PTHR1_CFP/YFP and PTHR1_Nluc/Halo618 (each N = 4). Data are expressed as box and whisker plots (a, d) or mean ± s.e.m (b, c, e, f). Difference was analyzed by two-way ANOVA followed by Bonferroni post hoc test. *p ≤ 0.05 vs. buffer